Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: Liver Transpl. 2016 Jan 29;22(3):324–332. doi: 10.1002/lt.24344

Figure 2.

Figure 2

Anti E1/E2 mAb AR4A (A,B) and EGCG (C,D) dose dependently inhibits infection with JFH-1 1a(A,C) and 2a(B,D) constructs in-vitro. Huh 7.5 cells were treated with EGCG simultaneous with addition of JFH-1 (HCVcc MOI 0.01). AR4A was pre-incubated with JFH-1 for 1 hour prior to addition to Huh 7.5 cells. Ten hours after JFH-1 addition, cells were washed and residual infection in Huh 7.5 cells was detected by NS5A staining at 48 hours. Mean % residual HCV infection is shown. Error bars indicate sem.